Calcitonin Screening in Nodular Thyroid Disease: Is There a Definitive Answer?

Area of Science:

• Endocrinology
• Oncology
• Thyroid disease diagnostics

Background:

• Calcitonin (Ctn) is a key marker for medullary thyroid carcinoma (MTC).
• The utility of Ctn screening in nodular thyroid disease (NTD) is debated.
• This study investigates hypercalcitoninemia frequency in NTD patients.

Purpose of the Study:

• To determine the prevalence of hypercalcitoninemia in patients with nodular thyroid disease.
• To assess the correlation between calcitonin levels and medullary thyroid carcinoma risk.
• To inform clinical decision-making regarding Ctn testing and MTC screening in NTD.

Main Methods:

• Retrospective analysis of 1,504 NTD patients' records from January 2011 to December 2015.
• Defined hypercalcitoninemia as Ctn levels > 10 pg/mL.
• Categorized patients into three groups based on Ctn levels: ≤10 pg/mL, 10-100 pg/mL, and ≥100 pg/mL.

Main Results:

• Hypercalcitoninemia was identified in 4.6% (69/1,504) of NTD patients.
• Medullary thyroid carcinoma (MTC) was histologically confirmed in 12 patients who underwent surgery.
• A higher Ctn level (≥100 pg/mL) was strongly associated with MTC diagnosis (100% confirmation) compared to intermediate levels (27% confirmation).

Conclusions:

• Hypercalcitoninemia occurs in a small percentage of NTD patients, but warrants careful evaluation.
• Calcitonin levels ≥100 pg/mL significantly elevate the risk of MTC.
• Endocrinologists play a crucial role in appropriate Ctn test interpretation and patient selection for surgery.